- Home
- CRDO vs BIIB Comparison
CRDO vs BIIB Comparison
Compare CRDO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDO
- BIIB
- Stock Information
- Founded
- CRDO 2008
- BIIB 1978
- Country
- CRDO Cayman Islands
- BIIB United States
- Employees
- CRDO N/A
- BIIB N/A
- Industry
- CRDO Semiconductors
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- CRDO Technology
- BIIB Health Care
- Exchange
- CRDO Nasdaq
- BIIB Nasdaq
- Market Cap
- CRDO 18.9B
- BIIB 18.7B
- IPO Year
- CRDO 2022
- BIIB 1991
- Fundamental
- Price
- CRDO $159.06
- BIIB $154.38
- Analyst Decision
- CRDO Strong Buy
- BIIB Buy
- Analyst Count
- CRDO 13
- BIIB 24
- Target Price
- CRDO $133.67
- BIIB $174.62
- AVG Volume (30 Days)
- CRDO 5.8M
- BIIB 1.6M
- Earning Date
- CRDO 12-01-2025
- BIIB 10-30-2025
- Dividend Yield
- CRDO N/A
- BIIB N/A
- EPS Growth
- CRDO N/A
- BIIB N/A
- EPS
- CRDO 0.67
- BIIB 10.97
- Revenue
- CRDO $600,135,000.00
- BIIB $10,065,900,000.00
- Revenue This Year
- CRDO $126.77
- BIIB $2.97
- Revenue Next Year
- CRDO $28.02
- BIIB N/A
- P/E Ratio
- CRDO $243.08
- BIIB $14.17
- Revenue Growth
- CRDO 175.81
- BIIB 4.77
- 52 Week Low
- CRDO $29.09
- BIIB $110.04
- 52 Week High
- CRDO $193.50
- BIIB $176.95
- Technical
- Relative Strength Index (RSI)
- CRDO 50.99
- BIIB 59.29
- Support Level
- CRDO $163.84
- BIIB $148.90
- Resistance Level
- CRDO $178.99
- BIIB $157.79
- Average True Range (ATR)
- CRDO 12.97
- BIIB 4.78
- MACD
- CRDO 0.30
- BIIB 0.43
- Stochastic Oscillator
- CRDO 43.84
- BIIB 82.77
About CRDO Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.